TNFRSF8 and systemic sclerosis: In the treatment of systemic sclerosis (SSc), based on the pathological features of elevated soluble CD30 levels in the serum of SSc patients and Th2-like cell activation, BV has emerged as a promising candidate drug for treating this disease.